Plus Therapeutics Inc
PSTV
Market Cap$7.67M
Close$
$-0.43
166.6% downside
Current Fair Value
166.6% downsideOvervalued by 166.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $7.67 Million |
|---|---|
| Enterprise Value | $10.96 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-4.24 |
| Beta | 0.67 |
| Outstanding Shares | 6,500,831 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -0.64 |
|---|---|
| PEG | 5.96 |
| Price to Sales | - |
| Price to Book Ratio | -0.32 |
| Enterprise Value to Revenue | 2.57 |
| Enterprise Value to EBIT | -0.75 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.31 |
| Debt to Equity | -0.38 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Plus Therapeutics Inc
2,018 employees
CEO: Marc Hedrick Plus Therapeutics is a clinical-stage pharmaceutical company whose radiotherapeutic portfolio is concentrated on nanoliposome-encapsulated radionuclides for several cancer targets. Central to the Company's drug development is a unique na...